Science & Technology

SkinPass™

A patented delivery system engineered to deliver active ingredients deeper and faster than conventional topical medications.

At ViaDerma, we’ve engineered a way to bypass the body's most stubborn barrier to provide healing exactly where it’s needed.

SkinPass

What is SkinPass™?

SkinPass™ is ViaDerma’s proprietary transdermal drug delivery platform—a breakthrough formulation and diffusion system designed to penetrate the epidermal barrier.

Traditional topical medications mostly remain on the outer layers of the skin. SkinPass™ is engineered to enhance topical absorption, helping ingredients penetrate deeper—directly to where they're needed.

By serving as the technological heart of our entire product pipeline, it allows us to transform conventional oral and injectable drugs into fast-acting, localized topicals.

SkinPass™ is ViaDerma’s proprietary transdermal drug delivery platform—a breakthrough formulation and diffusion system designed to penetrate the epidermal barrier.

By serving as the technological heart of our entire product pipeline, it allows us to transform conventional oral and injectable drugs into fast-acting, localized topicals.

Our Solution

Fast Absorption & Deep Penetration

Engineered delivery system promotes rapid penetration through the skin barrier. Reaches deeper skin layers where active ingredients can work most effectively.

Advanced Three-Part System

We utilize a specific formulation of tissue-penetrating solvents, diluents, and stabilizers to bypass the epidermal barrier.

Enhanced Efficacy

SkinPass™ forces active ingredients through bacterial cell walls, overwhelming "efflux pumps" that are the primary cause of drug resistance.

Organ Protection

Localized delivery minimizes strain on the kidneys and liver, eliminating the systemic risks associated with traditional drug delivery.

Licensing

License SkinPass™ Technology

What We Offer

Patent-protected delivery technology
Regulatory pathway guidance
Formulation development support

Ideal Partners

Pharmaceutical companies with topical product portfolios
Biotech firms developing novel topical therapeutics
Medical device companies in wound care and dermatology
Contract development and manufacturing organizations

Intellectual Property

A Protected Global Patent

Our technology is anchored by a robust and expanding intellectual property portfolio.

U.S. Patent No. 12,465,567: Awarded in 2025, this covers our "Enhanced Antibiotic and Drug Delivery" for both human and veterinary applications.

Strategic Exclusivity: Our portfolio includes 20 additional Continuation-in-Part (CIP) patent applications, establishing ViaDerma’s dominance in the transdermal delivery landscape.

Our technology is anchored by a robust and expanding intellectual property portfolio.

U.S. Patent No. 12,465,567: Awarded in 2025, this covers our "Enhanced Antibiotic and Drug Delivery" for both human and veterinary applications.

Strategic Exclusivity: Our portfolio includes 20 additional Continuation-in-Part (CIP) patent applications, establishing ViaDerma’s dominance in the transdermal delivery landscape.

Learn more on a call with a specialist

Schedule a free consultation with our sales team representative and discover how ViaDerma can bring innovation into your medical facility

Book a Call

Learn more on a call with a specialist

Schedule a free consultation with our sales team representative and discover how ViaDerma can bring innovation into your medical facility

Book a Call

Learn more on a call with a specialist

Schedule a free consultation with our sales team representative and discover how ViaDerma can bring innovation into your medical facility

Book a Call